(GDRX) Goodrx Holdings - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US38246G1085
GDRX: Prescription, Prices, Comparison, Subscriptions, Telehealth, Pharmacy
GoodRx Holdings Inc. (NASDAQ: GDRX) is a leader in the healthcare technology sector, dedicated to enhancing transparency and affordability in prescription drug pricing. Their platform empowers consumers by providing geographically relevant pricing comparisons and access to negotiated discounts, making it easier for individuals to save on medications. Beyond their core service, GoodRx offers a suite of healthcare solutions, including subscription services and partnerships with pharmaceutical manufacturers, further streamlining the healthcare experience.
The companys revenue is primarily generated through fees charged when consumers utilize their discount cards, leveraging their extensive network of pharmacy benefit managers and pharmacies. This model underscores their strategic position within the healthcare ecosystem. Notably, GoodRx expanded its offerings into telehealth services via GoodRx Care, providing convenient access to medical consultations and prescriptions, which aligns with the growing trend of digital health solutions.
Financially, GoodRx boasts a market capitalization of approximately $1.92 billion, with a forward P/E ratio of 13.91, indicating investor confidence in future profitability despite current earnings. Their price-to-book ratio of 2.76 and price-to-sales ratio of 2.43 highlight a valuation that reflects both their growth potential and market position. Since their IPO in 2020, GoodRx has demonstrated resilience and adaptability, making them a compelling consideration for investors and fund managers interested in the intersection of technology and healthcare.
With a strong foundation in bringing transparency to drug pricing, GoodRx continues to expand its services, solidifying its role as a key player in the healthcare technology landscape. Their strategic initiatives and partnerships position them well for sustained growth, offering a promising opportunity for those invested in innovative healthcare solutions.
Additional Sources for GDRX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GDRX Stock Overview
Market Cap in USD | 1,780m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2020-09-23 |
GDRX Stock Ratings
Growth 5y | -80.9% |
Fundamental | 30.6% |
Dividend | 0.0% |
Rel. Strength Industry | -35.3 |
Analysts | 3.88/5 |
Fair Price Momentum | 2.99 USD |
Fair Price DCF | 24.58 USD |
GDRX Dividends
No Dividends PaidGDRX Growth Ratios
Growth Correlation 3m | 40.2% |
Growth Correlation 12m | -68% |
Growth Correlation 5y | -72% |
CAGR 5y | -41.95% |
CAGR/Max DD 5y | -0.45 |
Sharpe Ratio 12m | -0.89 |
Alpha | -41.41 |
Beta | 0.39 |
Volatility | 61.28% |
Current Volume | 1063.9k |
Average Volume 20d | 1628.5k |
As of March 15, 2025, the stock is trading at USD 4.42 with a total of 1,063,947 shares traded.
Over the past week, the price has changed by -4.12%, over one month by -12.30%, over three months by -3.70% and over the past year by -34.71%.
Neither. Based on ValueRay Fundamental Analyses, Goodrx Holdings is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 30.58 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GDRX as of March 2025 is 2.99. This means that GDRX is currently overvalued and has a potential downside of -32.35%.
Goodrx Holdings has received a consensus analysts rating of 3.88. Therefor, it is recommend to buy GDRX.
- Strong Buy: 7
- Buy: 2
- Hold: 7
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, GDRX Goodrx Holdings will be worth about 3.2 in March 2026. The stock is currently trading at 4.42. This means that the stock has a potential downside of -26.7%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6.7 | 51.8% |
Analysts Target Price | 6.9 | 56.1% |
ValueRay Target Price | 3.2 | -26.7% |